Liposome Encapsulated Tyrosine Kinase Inhibitors to Treat Leukemia
Application
Lipid encapsulation of MRX-2843 for the treatment of leukemia.
Key Benefits
- Encapsulation of a tyrosine kinase inhibitor called MRX-2843 within a liposome improves its performance in an animal model of acute lymphoblastic leukemia.
- Systemic delivery of this therapeutic requires a lower dose and less frequent administration than oral delivery.
- A synergistic effect was observed when this was combined with a common leukemia chemotherapeutic.
- Has the potential to improve leukemia therapeutics by reducing the dosage amount and frequency.
Market Summary
Leukemia is a type of blood cancer that causes over 23,000 deaths annually, accounting for close to 4% of cancer deaths each year. Acute lymphoblastic leukemia is the most common type of cancer in children and is also a high risk in adults over the age of 50. While there are clinically available chemotherapeutics for treating this disease, 10-20% of acute lymphoblastic leukemia patients experience relapse. The global leukemia therapeutic market has high growth opportunities due to an increase in initiatives to diagnose and treat the disease.
Technical Summary
Researchers at Emory University and Children’s Healthcare of Atlanta have found that encapsulating a tyrosine kinase inhibitor, MRX-2843, in liposomes and delivering it systemically increases its performance in a mouse model of leukemia when compared to oral delivery of the unencapsulated drug. This therapeutic functions by targeting two targets of leukemia, MERTK and FLT3, and its unencapsulated form is being evaluated in clinical trials for leukemia.
Development Stage
Proof of concept animal data.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
|
|